<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03924856</url>
  </required_header>
  <id_info>
    <org_study_id>3475-866</org_study_id>
    <secondary_id>2018-003808-39</secondary_id>
    <secondary_id>MK-3475-866</secondary_id>
    <secondary_id>KEYNOTE-866</secondary_id>
    <secondary_id>194870</secondary_id>
    <nct_id>NCT03924856</nct_id>
  </id_info>
  <brief_title>Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)</brief_title>
  <acronym>KEYNOTE-866</acronym>
  <official_title>A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-866)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to
      pembrolizumab plus chemotherapy in cisplatin eligible patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Anticipated">January 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response (pCR) Rate in All Participants</measure>
    <time_frame>Up to approximately 4 months (Time of surgery)</time_frame>
    <description>Pathologic complete response rate is defined as the percentage of participants having pCR. pCR is defined as absence of viable tumor (pT0) in examined tissue from RC and PLND, as determined centrally.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate in Participants Whose Tumors Express PD-L1 Combined Positive Score (CPS) ≥10</measure>
    <time_frame>Up to approximately 4 months (Time of surgery)</time_frame>
    <description>Pathologic complete response rate is defined as the percentage of participants having pCR. pCR is defined as pT0 in examined tissue from RC and PLND, as determined centrally.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-Free Survival (EFS) in All Participants</measure>
    <time_frame>Up to approximately 5.5 years</time_frame>
    <description>EFS is defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes RC surgery or failure to undergo RC surgery in participants with residual disease, gross residual disease left behind at the time of surgery, local or distant recurrence based on blinded independent central review (BICR) assessments, or death due to any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-Free Survival in Participants Whose Tumors Express PD-L1, CPS ≥10</measure>
    <time_frame>Up to approximately 5.5 years</time_frame>
    <description>EFS is defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes RC surgery or failure to undergo RC surgery in participants with residual disease, gross residual disease left behind at the time of surgery, local or distant recurrence based on blinded independent central review (BICR) assessments, or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in All Participants</measure>
    <time_frame>Up to approximately 5.5 years</time_frame>
    <description>Overall survival is defined as the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in Participants Whose Tumors Express PD-L1, CPS ≥10</measure>
    <time_frame>Up to approximately 5.5 years</time_frame>
    <description>Overall survival is defined as the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS) in All Participants</measure>
    <time_frame>From approximately 5 months up to approximately 5.5 years</time_frame>
    <description>DFS is defined as the time from post-surgery baseline scan until the first occurrence of either:
Local or distant recurrence as assessed by CT or MRI (BICR) and/or biopsy
Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival in Participants Whose Tumors Express PD-L1, CPS ≥10</measure>
    <time_frame>From approximately 5 months up to approximately 5.5 years</time_frame>
    <description>DFS is defined as the time from post-surgery baseline scan until the first occurrence of either:
Local or distant recurrence as assessed by CT or MRI (BICR) and/or biopsy
Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic Downstaging (pDS) Rate in All Participants</measure>
    <time_frame>Up to approximately 4 months (Time of surgery)</time_frame>
    <description>Pathologic downstaging rate is defined as the percentage of participants having pDS. pDS is defined as participants with a tumor classification of &lt;pT2 (includes pT0, pTis, pTa, pT1) and N0 in examined tissue from RC and PLND.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic Downstaging (pDS) Rate in Participants Whose Tumors Express PD-L1, CPS ≥10</measure>
    <time_frame>Up to approximately 4 months (Time of surgery)</time_frame>
    <description>Pathologic downstaging rate is defined as the percentage of participants having pDS. pDS is defined as participants with a tumor classification of &lt;pT2 (includes pT0, pTis, pTa, pT1) and N0 in examined tissue from RC and PLND.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 5.5 years</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Discontinuing Study Drug Due to an AE</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Perioperative Complications</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-Reported Outcomes from Baseline in Total Score of Functional Assessment of Cancer Therapy - General (FACT-G)</measure>
    <time_frame>Baseline and time of last patient-reported outcome assessment (up to approximately 5.5 years)</time_frame>
    <description>The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score can range from 0 to 108.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-Reported Outcomes from Baseline in Total Score of Functional Assessment of Cancer Therapy-Bladder Cancer-Specific Subscale/Symptom Index for Participants Undergoing Cystectomy (Total Score FACT BI-Cys)</measure>
    <time_frame>Baseline and time of last patient-reported outcome assessment (up to approximately 5.5 years)</time_frame>
    <description>Total Score of FACT BI-Cys is the sum of FACT-G total score and FACT-Bl-Cys score. FACT-Bl-Cys contains 17 items on the bowel, bladder, and sexual symptoms following cystectomy. The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score of FACT-Bl-Cys can range from 0 to 168.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-Reported Outcomes from Baseline in FACT-Bl-Cys-Trial Outcome Index (TOI)</measure>
    <time_frame>Baseline and time of last patient-reported outcome assessment (up to approximately 5.5 years)</time_frame>
    <description>FACT-Bl-Cys Trial Outcome Index (TOI) is the sum of FACT-G PWB score, FWB score, and FACT-Bl-Cys score. FACT-Bl-Cys contains 17 items on the bowel, bladder, and sexual symptoms following cystectomy. The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score of FACT-Bl-Cys TOI can range from 0 to 116.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-Reported Outcomes from Baseline in EuroQol Five-Dimensional Questionnaire (EQ-5D-5L) Visual Analog Score (VAS)</measure>
    <time_frame>Baseline and time of last patient-reported outcome assessment (up to approximately 5.5 years)</time_frame>
    <description>The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. In the EQ-5D-5L VAS, the participant rates his or her general state of health at the time of the assessment on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-Reported Outcomes from Baseline in EQ-5D-5L Utility Score</measure>
    <time_frame>Baseline and time of last patient-reported outcome assessment (up to approximately 5.5 years)</time_frame>
    <description>The EQ-5D-5L is a standardized instrument for use as a measure of health outcome and includes 5 health state dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 5-point scale from 1 (no problem) to 5 (unable to/extreme problems), for a total range of 5 to 25 points, with a lower score indicating a better health outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration (TTD) in the Total Score of FACT-G</measure>
    <time_frame>Up to approximately 5.5 years</time_frame>
    <description>The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0-4, with higher scores indicating higher HRQoL. TTD is defined as the time from baseline to the first onset of patient-reported outcomes (PRO) deterioration. For the FACT-G questionnaire, deteriorations are defined as a decrease of 7 points or more (out of 108) from baseline in total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in EQ-5D-5L VAS</measure>
    <time_frame>Up to approximately 5.5 years</time_frame>
    <description>The EQ-5D-5L is a standardized instrument for use as a measure of health outcome and includes 5 health state dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In the EQ-5D-5L VAS, the participant rates his or her general state of health at the time of the assessment on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. TTD is defined as the time from baseline to the first onset of PRO deterioration. For the EQ 5D-5L, deterioration is defined as a decrease of 7 points or more from baseline in the VAS.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">790</enrollment>
  <condition>Urinary Bladder Cancer, Muscle-invasive</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab + Gemcitabine + Cisplatin + Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 4 preoperative cycles of pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative pembrolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Gemcitabine + Cisplatin + Surgery</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received 4 preoperative cycles of placebo to pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative placebo to pembrolizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle</description>
    <arm_group_label>Pembrolizumab + Gemcitabine + Cisplatin + Surgery</arm_group_label>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000 mg/m^2, IV infusion on Days 1 and 8 of each 21-day cycle</description>
    <arm_group_label>Pembrolizumab + Gemcitabine + Cisplatin + Surgery</arm_group_label>
    <arm_group_label>Placebo + Gemcitabine + Cisplatin + Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 70 mg/m^2, IV infusion on Day 1 of each 21-day cycle</description>
    <arm_group_label>Pembrolizumab + Gemcitabine + Cisplatin + Surgery</arm_group_label>
    <arm_group_label>Placebo + Gemcitabine + Cisplatin + Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])</intervention_name>
    <description>Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.</description>
    <arm_group_label>Pembrolizumab + Gemcitabine + Cisplatin + Surgery</arm_group_label>
    <arm_group_label>Placebo + Gemcitabine + Cisplatin + Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to pembrolizumab by IV infusion, given on Day 1 of each 21-day cycle</description>
    <arm_group_label>Placebo + Gemcitabine + Cisplatin + Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Have a histologically confirmed diagnosis of muscle invasive bladder cancer (T2-T4aN0M0)
        with predominant (≥50%) urothelial histology (histology and presence of muscle invasion to
        be confirmed by BICR): Participants with mixed histology are eligible provided the
        urothelial component is ≥50%.

        Participants whose tumors contain any neuroendocrine component are not eligible.

        Urothelial carcinomas not originating from the bladder (e.g., upper tract [ureters, renal
        pelvis], urethra) are not eligible.

          -  Have clinically non-metastatic bladder cancer (N0M0) determined by imaging (computed
             tomography (CT) chest or magnetic resonance imaging (MRI) of the abdomen/pelvis.

          -  Be deemed eligible for RC + PLND by his/her urologist and/or oncologist and agree to
             undergo curative intent standard RC + PLND (including prostatectomy if applicable).

          -  Have a transurethral resection (TUR) of a bladder tumor that is submitted and adequate
             to determine histology, muscle invasion, and PD-L1 status by central pathology vendor.

          -  Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Have demonstrated adequate organ function.

        Exclusion Criteria:

          -  Has a known additional malignancy that is progressing or has required active
             anti-cancer treatment ≤3 years of study randomization with certain exceptions.

          -  Has received any prior systemic anti-neoplastic treatment for MIBC.

          -  Is cisplatin-ineligible, as defined by meeting any one of the study criteria.

          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with
             an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,
             CTLA-4, OX-40, CD137).

          -  Has received therapy with hematopoietic growth factor such as granulocyte-colony
             stimulating factor (G-CSF) or granulocyte-monocyte-colony stimulating factor(GM-CSF)
             in 14 days prior to randomization.

          -  Has received prior systemic anti-cancer therapy including investigational agents
             within 3 years of randomization.

          -  Has received any prior radiotherapy to the bladder.

          -  Has received a live vaccine within 30 days prior to the first dose of study drug.

          -  Is currently participating in or has participated in a study of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             study intervention.

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             or any other form of immunosuppressive therapy within 7 days prior the first dose of
             study drug.

          -  Has hypersensitivity to monoclonal antibodies (mAbs, including pembrolizumab) and/or
             any of their excipients.

          -  Has severe hypersensitivity (≥Grade 3) to cisplatin and/or gemcitabine and any of
             their excipients.

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years

          -  Has a history of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis.

          -  Has an active infection requiring systemic therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scripps MD Anderson ( Site 0010)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>858-554-8367</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Saint John's Health Center ( Site 0075)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-582-7456</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center ( Site 0022)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-444-2198</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advent Health ( Site 0005)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>407-303-2038</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parkview Cancer Institute ( Site 0077)</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>260-266-9167</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center ( Site 0004)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>317-274-7477</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center ( Site 0049)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>504-842-9917</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New England Cancer Specialists ( Site 0070)</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>207-303-3423</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center ( Site 0051)</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>508-334-5539</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital ( Site 0039)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-916-8862</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Saint Louis ( Site 0064)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-251-7061</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center ( Site 0015)</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>973-971-5373</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center ( Site 0045)</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>505-925-0421</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York University Perlmutter Cancer Center ( Site 0008)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-731-5820</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center ( Site 0038)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>216-844-6031</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0021)</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>918-505-3200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portland VA Medical Center ( Site 0084)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>503220826256128</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital ( Site 0048)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>412-359-8373</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center ( Site 0063)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-563-1602</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Texas Veterans Healthcare System ( Site 0057)</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>254-743-1226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute ( Site 0007)</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>571-472-0623</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties, PLLC ( Site 0061)</name>
      <address>
        <city>Puyallup</city>
        <state>Washington</state>
        <zip>98372</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>253-428-8753</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0033)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-606-7486</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charleston Area Medical Center ( Site 0023)</name>
      <address>
        <city>Charles Town</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>304-388-9945</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid North Coast Cancer Institute ( Site 1256)</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61265814053</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southside Cancer Care Centre ( Site 1252)</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2228</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61285569300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cairns Base Hospital ( Site 1257)</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61742268085</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastern Health ( Site 1255)</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61398953585</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peninsula Health Frankston Hospital ( Site 1258)</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61397848520</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Brussel ( Site 0358)</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-Capitale, Region De</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3224776415</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur Site de Godinne ( Site 0354)</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3281422111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>O.L.V. Ziekenhuis Aalst ( Site 0356)</name>
      <address>
        <city>Aalst</city>
        <state>Oost-Vlaanderen</state>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3253724378</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares Gent ( Site 0353)</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3292469522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre ( Site 0100)</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4034762543</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Health Authority ( Site 0109)</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>9024735122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre ( Site 0103)</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>61354966663743</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health ( Site 0104)</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>9055768711</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Research Institute ( Site 0110)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>416480500082139</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre ( Site 0107)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4169462246</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0105)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>51425234005853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0111)</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>418525444420414</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev og Gentofte Hospital. ( Site 0402)</name>
      <address>
        <city>Herlev</city>
        <state>Hovedstaden</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4538686518</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet University Hospital ( Site 0401)</name>
      <address>
        <city>Kobenhavn</city>
        <state>Hovedstaden</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4534458403</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital ( Site 0403)</name>
      <address>
        <city>Odense</city>
        <state>Syddanmark</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4524998173</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard ( Site 0465)</name>
      <address>
        <city>Lyon</city>
        <state>Auvergne</state>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33478782828</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse ( Site 0459)</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33231455002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Armoricain de Radiotherapie Imagerie medicale et Oncologie ( Site 0457)</name>
      <address>
        <city>Plerin</city>
        <state>Cotes-d'Armor</state>
        <zip>22190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33296752216</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux- Hopital Saint Andre ( Site 0456)</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33556795808</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Foch ( Site 0483)</name>
      <address>
        <city>Suresnes</city>
        <state>Hauts-de-Seine</state>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+0033146251979</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hopital Saint-Eloi ( Site 0469)</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33467336733</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de l Ouest Site Paul Papin ( Site 0453)</name>
      <address>
        <city>Angers</city>
        <state>Maine-et-Loire</state>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33241352734</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Belle Isle ( Site 0452)</name>
      <address>
        <city>Metz</city>
        <state>Moselle</state>
        <zip>57045</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33357841590</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine ( Site 0454)</name>
      <address>
        <city>Avignon</city>
        <state>Provence-Alpes-Cote-d'Azur</state>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33490276090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin ( Site 0460)</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Puy-de-Dome</state>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33473278117</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo ( Site 0463)</name>
      <address>
        <city>Le Mans</city>
        <state>Sarthe</state>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33243479493</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0502)</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wurttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4970712987235</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Erlangen ( Site 0505)</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4991318333122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Magdeburg A.o.R. ( Site 0516)</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493916715036</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus ( Site 0519)</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493514582157</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein-Campus Lubeck ( Site 0512)</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4945150043616</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin Berlin ( Site 0515)</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4930450515288</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum am Urban ( Site 0522)</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4930130226303</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem AOK ( Site 1009)</name>
      <address>
        <city>Pecs</city>
        <state>Baranya</state>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36302457110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SZTE Szent-Gyorgyi Albert Klinikai Kozpont ( Site 1010)</name>
      <address>
        <city>Szeged</city>
        <state>Csongrad</state>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+366262545259</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktato Korhaz ( Site 1012)</name>
      <address>
        <city>Gyor</city>
        <state>Gyor-Moson-Sopron</state>
        <zip>9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36209323256</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bajcsy Zsilinszki Korhaz es Rendelointezet ( Site 1001)</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36703815172</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont ( Site 1006)</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3652255585</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital ( Site 0722)</name>
      <address>
        <city>Cork</city>
        <zip>T12 DC4A</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+353214920052</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tallaght University Hospital ( Site 0710)</name>
      <address>
        <city>Dublin</city>
        <zip>D24 DH74</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35314144259</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Waterford ( Site 0723)</name>
      <address>
        <city>Waterford</city>
        <zip>X91 ER8E</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35351848934</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center ( Site 0806)</name>
      <address>
        <city>Beer Sheva</city>
        <state>HaDarom</state>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972523514527</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center ( Site 0803)</name>
      <address>
        <city>Kfar Saba</city>
        <state>HaMerkaz</state>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97297471606</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center ( Site 0804)</name>
      <address>
        <city>Petach Tikva</city>
        <state>HaMerkaz</state>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97239378074</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center ( Site 0805)</name>
      <address>
        <city>Zerifin</city>
        <state>HaMerkaz</state>
        <zip>7030001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97289779715</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ha Emek Medical Center ( Site 0808)</name>
      <address>
        <city>Afula</city>
        <state>HaTsafon</state>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97246495723</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 0802)</name>
      <address>
        <city>Haifa</city>
        <state>Heifa</state>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97247776750</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center ( Site 0801)</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tell Abib</state>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235302191</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center ( Site 0807)</name>
      <address>
        <city>Tel Aviv</city>
        <state>Tell Abib</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97236973413</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center ( Site 0809)</name>
      <address>
        <city>Jerusalem</city>
        <state>Yerushalayim</state>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97226666331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico Vittorio Emanuele - Presidio Gaspare Rodolico ( Site 0559)</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390953781518</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Studio e Cura dei Tumori ( Site 0551)</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390223902402</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico di Modena ( Site 0553)</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390594222648</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Per Lo Studio E La Cura Dei Tumori ( Site 0552)</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+39815903637</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri IRCCS. ( Site 0554)</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390382592265</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo Forlanini ( Site 0560)</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390658704356</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Gemelli di Roma ( Site 0558)</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390630154953</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria Terni ( Site 0557)</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+393294092709</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hirosaki University Hospital ( Site 1502)</name>
      <address>
        <city>Hirosaki</city>
        <state>Aomori</state>
        <zip>036-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81172335111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East ( Site 1504)</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81471331111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ehime University Hospital ( Site 1508)</name>
      <address>
        <city>Toon</city>
        <state>Ehime</state>
        <zip>791-0295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81899645111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sapporo Medical University Hospital ( Site 1501)</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81116112111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital ( Site 1503)</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81298533900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yokosuka Kyosai Hospital ( Site 1509)</name>
      <address>
        <city>Yokosuka</city>
        <state>Kanagawa</state>
        <zip>238-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81468222710</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital ( Site 1510)</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81744223051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University International Medical Center ( Site 1505)</name>
      <address>
        <city>Hidaka</city>
        <state>Saitama</state>
        <zip>350-1298</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81429844111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiba Cancer Center ( Site 1506)</name>
      <address>
        <city>Chiba</city>
        <zip>260-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81432645431</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harasanshin Hospital ( Site 1515)</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81922913434</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Hiroshima Citizens Hospital ( Site 1513)</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81822212291</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagano Municipal Hospital ( Site 1516)</name>
      <address>
        <city>Nagano</city>
        <zip>381-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81262951199</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital ( Site 1512)</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81666452121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokushima University Hospital ( Site 1514)</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81886313111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Hospital, Tokyo Medical And Dental University ( Site 1517)</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81338136111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center ( Site 1354)</name>
      <address>
        <city>Goyang-si</city>
        <state>Kyonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82319201678</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital ( Site 1356)</name>
      <address>
        <city>Seongnam-si</city>
        <state>Kyonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82317877351</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital ( Site 1351)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+821099288097</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 1352)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82220720361</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 1355)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82230103980</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 1353)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82234103557</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Urologia Avanzada del Noreste S.A. de C.V. ( Site 0254)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>66269</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+528180267452</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V. ( Site 0300)</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20010</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+524494735100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Estatal de Cancerologia de Chihuahua ( Site 0253)</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+526141420241</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia ( Site 0256)</name>
      <address>
        <city>Tlalpan</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525555734772</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 1062)</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48601143281</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii im.prof. F. Lukaszczyka w Bydgoszczy ( Site 1068)</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48501446778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Europejskie Centrum Zdrowia Otwock ( Site 1057)</name>
      <address>
        <city>Otwock</city>
        <state>Mazowieckie</state>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48601200599</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Magodent Szpital Elblaska ( Site 1051)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-748</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48691666578</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 1060)</name>
      <address>
        <city>Bielsko-Biala</city>
        <state>Slaskie</state>
        <zip>43-300</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48606399091</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ivanovo Regional Oncology Dispensary ( Site 0852)</name>
      <address>
        <city>Ivanovo</city>
        <state>Ivanovskaya Oblast'</state>
        <zip>153040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79106672833</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0861)</name>
      <address>
        <city>Krasnoyarsk</city>
        <state>Krasnoyarskiy Kray</state>
        <zip>660133</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79135349316</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kursk Regional Clinical Oncology Dispensary ( Site 0854)</name>
      <address>
        <city>Kursk</city>
        <state>Kurskaya Oblast'</state>
        <zip>305524</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79103113475</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leningrad Regional Oncology Center ( Site 0868)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Leningradskaya Oblast'</state>
        <zip>188663</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79219410363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital with outpatient Clinic ( Site 0856)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79031691379</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bayandin Murmansk Regional Clinical Hospital ( Site 0859)</name>
      <address>
        <city>Murmansk</city>
        <state>Murmanskaya Oblast'</state>
        <zip>183057</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79217252994</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Volga District Medical Center Federal Medical and Biological Agency ( Site 0857)</name>
      <address>
        <city>Nizhny Novgorod</city>
        <state>Nizhegorodskaya Oblast'</state>
        <zip>603074</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78314216977</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omsk Clinical Oncology Dispensary ( Site 0865)</name>
      <address>
        <city>Omsk</city>
        <state>Omskaya Oblast</state>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79139885114</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Saint Luka ( Site 0867)</name>
      <address>
        <city>St. Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79817217460</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University n.a. V.I.Razumovskiy ( Site 0866)</name>
      <address>
        <city>Saratov</city>
        <state>Saratovskaya Oblast'</state>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79271233801</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar ( Site 0653)</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932483139</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. de Gerona Dr. Josep Trueta ( Site 0651)</name>
      <address>
        <city>Girona</city>
        <state>Girona [Gerona]</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+349722258284028</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quiron Madrid ( Site 0657)</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914521987</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncologia - IVO ( Site 0662)</name>
      <address>
        <city>Valencia</city>
        <state>Valenciana, Comunitat</state>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34961114605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara ( Site 0654)</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34927256200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal ( Site 0660)</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913368263</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Carlos ( Site 0663)</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+349133030007554</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 0661)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34912071138</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Sra. de Valme ( Site 0658)</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34955015000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laenssjukhuset Ryhov ( Site 1205)</name>
      <address>
        <city>Jonkoping</city>
        <state>Jonkopings Lan [se-06]</state>
        <zip>551 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46102428577</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset ( Site 1201)</name>
      <address>
        <city>Uppsala</city>
        <state>Uppsala Lan [se-03]</state>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46186110000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancercentrum ( Site 1204)</name>
      <address>
        <city>Umea</city>
        <state>Vasterbottens Lan [se-24]</state>
        <zip>901 89</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46907853296</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital. ( Site 1451)</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6622011671</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital ( Site 1452)</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6624194488</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiangmai Hospital ( Site 1453)</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+66539455324</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tıp Fakultesi ( Site 0911)</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905327233093</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0910)</name>
      <address>
        <city>Istanbul</city>
        <zip>34096</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905324167355</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medeniyet Uni. Goztepe Egitim ve Arast. Hast. ( Site 0906)</name>
      <address>
        <city>Istanbul</city>
        <zip>34732</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905324543079</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitesi Pendik Egitim ve Arastirma Hastanesi ( Site 0901)</name>
      <address>
        <city>Istanbul</city>
        <zip>34899</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905333832234</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi ( Site 0909)</name>
      <address>
        <city>Konya</city>
        <zip>42080</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905322679838</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sakarya Universitesi Tip Fakultesi ( Site 0913)</name>
      <address>
        <city>Sakarya</city>
        <zip>54290</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905054785576</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karadeniz Teknik Universitesi Tip Fakultesi Farabi Hastanesi ( Site 0904)</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905052292035</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cherkasy Regional Oncology Dispensary ( Site 0959)</name>
      <address>
        <city>Cherkasy</city>
        <state>Cherkaska Oblast</state>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380501606360</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI Dnipr Regional Clinical Hospital named after I.I. Mechnikov ( Site 0963)</name>
      <address>
        <city>Dnipropetrovsk</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380567134785</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Oncological Hospital ( Site 0956)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49055</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380687400930</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk City Multidiscipline Clinical Hosp. 4 of DRC ( Site 0951)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380675625054</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reg. Clinical Center of Urology and Nephrology n.a. V. I. Shapoval ( Site 0969)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380577387134</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Oncology Center of Kharkiv ( Site 0958)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380508266088</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute of the MoH of Ukraine ( Site 0962)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>03022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380672365175</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Oncology Center ( Site 0960)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380667027558</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lviv Regional Clinical Hospital ( Site 0955)</name>
      <address>
        <city>Lviv</city>
        <state>Lvivska Oblast</state>
        <zip>79000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380677280861</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 0967)</name>
      <address>
        <city>Lviv</city>
        <state>Lvivska Oblast</state>
        <zip>79031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380973317578</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kent and Canterbury Hospital ( Site 0709)</name>
      <address>
        <city>Canterbury</city>
        <state>Kent</state>
        <zip>CT1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441227766877</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust ( Site 0721)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442033117627</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norfolk &amp; Norwich University Hospital NHS Foundation Trust ( Site 0725)</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441603287226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital ( Site 0703)</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>441872250000</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://merckoncologyclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trials Information</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death-1 (PD1, PD-1)</keyword>
  <keyword>Programmed Death-Ligand 1 (PDL1, PD-L1)</keyword>
  <keyword>Pembrolizumab (MK-3475)</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Muscle Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

